Supplemental Tables for:
"Relative Dose Intensity of Chemotherapy and Survival in Advanced Stage Solid Tumor Cancer Patients: A Systematic Review and Meta-Analysis"
Carrie M Nielson et al.

Table S1: Detailed search strategy

Database	PubMed	Embase	Web of Science
Search String	("Neoplasms"[MeSH] NOT "hematologic neoplasms" [MeSH]) AND "drug therapy" [MeSH] AND "relative dose intensity" [All Fields] AND ("overall survival" [All Fields] OR "progression-free survival" [All Fields] OR "disease-free survival" [MeSH] OR "recurrence-free survival" [All Fields] OR "survival" [MeSH] OR "survival analysis" [MeSH] OR "survival rate" [MeSH])	(('neoplas*'/exp OR 'cancer'/exp OR 'malignan*'/exp) NOT 'hematologic malinan*'/exp) AND ('relative dose intensity') AND ('overall survival'/exp OR 'progression-free survival'/exp OR 'disease-free survival'/exp OR 'recurrence-free survival'/exp OR surviv*/exp)	(neoplas* OR cancer OR malignan*) AND ("relative dose intensity") AND (overall survival OR progression-free survival OR disease-free survival OR relapse-free survival OR surviv*)
Filters	English language only	English language only	English language only
Date Searched	07/02/2020	07/02/2020	07/02/2020
Number of Hits	263	835	344

Supplemental Tables for:
"Relative Dose Intensity of Chemotherapy and Survival in Advanced Stage Solid Tumor Cancer Patients: A Systematic Review and Meta-Analysis"
Carrie M Nielson et al.

Table S2: Studies of taxane- and gemcitabine-based chemotherapy regimens

Author (Year)	Tumor Type	Chemotherapy Regimen	Patient N	RDI Comparison	OS	PFS
Fernández (2018) [19]	Pancreas	Nab-paclitaxel, gemcitabine	210	<85% vs. ≥85%	p = 0.754 in favor of RDI <85% (median OS 7.2 vs. 7.0 months)	p = 0.704 in favor of RDI ≥85% (median PFS 5.0 vs. 5.2 months)
Perez-Fidalgo (2014) [45]	Breast	Anthracycline, taxane-based chemotherapy	231	<85% vs. ≥85%	p = 0.026 in favor of RDI ≥85% (5-year OS rate 80% vs. 97%)	NR
Ishimoto (2019) [30]	Pancreas	Nab-paclitaxel, gemcitabine	27	<63.6% vs. ≥63.6%	p = 0.984	NR
Kushnir (2019) [31]	Prostate	Docetaxel	81	10% increase in RDI	HR 0.83 (95% CI: 0.72–0.96) p = 0.0117	NR
Kanazawa (2017) [16]	Gastric	Nab-paclitaxel	14	<80% vs. ≥80%	p = 0.03 in favor of RDI ≥80% (median OS 8.2 vs. 14.3 months)	p = 0.02 in favor of RDI ≥80% (median PFS 4 vs. 11.8 months)
Ishigaki (2017) [17]	Pancreas	Nab-paclitaxel, gemcitabine	102	<77% vs. ≥77%	p = 0.1 in favor of RDI <77% (median OS 410 vs. 312 days)	p = 0.33 in favor of RDI <77% (median PFS 196 vs. 183 days)
Saito (2017) [32]	Pancreas	Nab-paclitaxel, gemcitabine (first-line)	80	<70% vs. ≥70%	HR 1.70 (95% CI: 0.63–4.25) p = 0.28	NR
		Nab-paclitaxel, gemcitabine (refractory/recurrent)	80	<70% vs. ≥70%	HR 2.44 (95% CI: 1.07–5.49) p = 0.04	NR

Supplemental Tables for:
"Relative Dose Intensity of Chemotherapy and Survival in Advanced Stage Solid Tumor Cancer Patients: A Systematic Review and Meta-Analysis"
Carrie M Nielson et al.

Author (Year)	Tumor Type	Chemotherapy Regimen	Patient N	RDI Comparison	OS	PFS
Fukuchi (2016) [27]	Gastric	Nab-paclitaxel	37	<90% vs. ≥90%	NR	OR 0.89 (95% CI: 0.55–1.42)

CI, confidence interval; HR, hazard ratio; NR, not reported; OR, odds ratio; OS, overall survival; PFS, progression-free survival; RDI, relative dose intensity